Results 151 to 160 of about 21,372 (208)

Longer survival and favorable healthcare resource utilization of tagraxofusp versus venetoclax in patients with blastic plasmacytoid dendritic cell neoplasm: results of a real-world analysis. [PDF]

Front Oncol
Stein AS, Guru Murthy GS, Vachhani P, Iyer S, Goldschmidt D, Gao Y, Katsetos J, Pelletier C, Kovacsovics T.   +8 more
europepmc   +1 more source

Long-term outcomes of azacitidine, venetoclax, and gilteritinib in newly diagnosed FLT3-mutated AML. [PDF]

Blood Adv
Short NJ, Kantarjian H, Daver N, Azevedo RS, Karrar O, DiNardo CD, Kadia T, Yilmaz M, Maroun M, Hachem M, Borthakur G, Issa GC, Shpall EJ, Popat U, Huang X, Qiao W, Nasr L, Macaron W, Abramova R, Garcia-Manero G, Konopleva M, Ravandi F.   +21 more
europepmc   +1 more source

Dynamic Switching of Apoptosis-Modulating Bim Heterodimers in Response to BH3 Mimetics in Xenograft Models of Hematologic Malignancies. [PDF]

Mol Cancer Ther
Govindharajulu JP, Fluss S, Hollingshead MG, Gillette W, Esposito D, Newton DL, Stockwin LH, Chen L, Jiwani S, Dougherty K, Andrews O, Johnson BC, Evrard YA, Parchment RE, Doroshow JH, Srivastava AK.   +15 more
europepmc   +1 more source

A functional prognostic model predicts progression-free survival in patients with relapsed chronic lymphocytic leukemia treated with ibrutinib + venetoclax. [PDF]

Hemasphere
Hermansen JU, Kong W, Brodersen AM, Yin Y, Urban A, Rein ID, He L, Agius R, Teglgaard RS, Rousu J, Brieghel C, Kersting S, Levin MD, Tran HTT, Mattsson M, Ranti J, Veldhuis GJ, da Cunha-Bang C, Mous R, Dubois J, Kater AP, Enserink JM, Niemann CU, Aittokallio T, Skånland SS.   +24 more
europepmc   +1 more source

Dynamic genetic and nongenetic RAS-pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy. [PDF]

Blood
Kennedy VE, Peretz CAC, Walia A, Chyla B, Sun Y, Hill J, Tran E, Koh AD, Ferng T, Pintar S, Jones MF, Popescu B, Lomeli I, Chehab F, Murad N, John A, Roy R, Olshen A, Berryhill CA, Davis C, Angus SP, Rivera JM, Meshulam A, Stieglitz E, Joshi S, Traer E, Dail M, Hamidi H, Altman JK, Daver N, Levis M, McCloskey J, Perl AE, Smith CC.   +33 more
europepmc   +1 more source

Abstracts of 14th International Symposium on Hodgkin Lymphoma

HemaSphere, Volume 10, Issue S2, October 2026.
wiley   +1 more source

Targeting BCL-2 through Deep Learning-Based Drug Repurposing: A Multimodal Approach Combining Diffusion-Based Generative Modeling, Neural Relational Inference, and In Vitro Validation. [PDF]

J Chem Inf Model
Sayyah E, Tunç H, Çelebi A, Avşar T, Durdağı S.   +4 more
europepmc   +1 more source

Liposomal-Mitoxantrone Overcomes Acquired Resistance and Enhances Venetoclax Synergy in AML-Mechanistic Insights and Preliminary Clinical Evidence. [PDF]

Int J Nanomedicine
Luo K, Hui Y, Shen H, Yan L, Zeng Y, Zhou L, Wang M, Wang J, Liu M, Wei H.   +9 more
europepmc   +1 more source

The Impact of Induction With Azacitidine and Venetoclax Versus Intensive Chemotherapy on Outcomes After Allogeneic Hematopoietic Cell Transplantation for Newly Diagnosed Acute Myeloid Leukemia. [PDF]

J Hematol
Wirk B, Hawila R.
europepmc   +1 more source

Venetoclax plus azacitidine in higher-risk myelodysplastic syndromes: a treatment-purpose framework for interpreting response depth. [PDF]

Front Med (Lausanne)
Zou X, Bu J, Chu A, Shi L, Zhang Z, Zheng Q, Luo M.   +6 more
europepmc   +1 more source